Wu Xuanxuan, Zhu Zengjun, Zhang Jian, Tian Maojin, Zhao Peiqing
School of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong, China.
Center of Translational Medicine, Zibo Central Hospital, Shandong Second Medical University, 54 Gongqingtuan Xi Road, Zibo, 255036, Shandong, China.
Clin Transl Oncol. 2025 Jan 8. doi: 10.1007/s12094-024-03835-4.
Programmed Death Protein-1 (PD-1) is a cell surface receptor that serves as a checkpoint for T cells, playing a pivotal role in regulating T-cell apoptosis. The binding of PD-1 to its ligand, Programmed Death Ligand 1 (PD-L1), inhibits anti-tumor immunity by suppressing T-cell activation signals. Indeed, the PD-1/PD-L1 pathway governs the induction and maintenance of immune tolerance within the tumor microenvironment. Consequently, the regulation of PD-1/PD-L1 immune checkpoint expression is of paramount importance. This review summarizes the mechanisms governing PD1/PD-L1 expression at various stages, including transcription, post-transcription (mRNA processing), and post-translation (protein modifications), as well as immunotherapy targeting PD1/PD-L1, aiming to further explore novel strategies for tumor immunotherapy.
程序性死亡蛋白-1（PD-1）是一种细胞表面受体，作为T细胞的检查点，在调节T细胞凋亡中起关键作用。PD-1与其配体程序性死亡配体1（PD-L1）的结合通过抑制T细胞激活信号来抑制抗肿瘤免疫。实际上，PD-1/PD-L1通路控制着肿瘤微环境中免疫耐受的诱导和维持。因此，PD-1/PD-L1免疫检查点表达的调节至关重要。本综述总结了在各个阶段控制PD1/PD-L1表达的机制，包括转录、转录后（mRNA加工）和翻译后（蛋白质修饰），以及针对PD1/PD-L1的免疫疗法，旨在进一步探索肿瘤免疫治疗的新策略。
